"The
Report PharmaPoint: Bipolar Disorder - Global Drug Forecast and
Market Analysis to 2024 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Bipolar
disorder is a mental disorder characterized by periods of mania and
depression. The frequency, severity, and pattern of these episodes
can vary considerably over time and between individuals, making
bipolar disorder one of the most challenging psychiatric disorders to
manage. The bipolar disorder market is widely genericized, with
additional key brands expected to face patent or data exclusivity
expiries during the forecast period. The bipolar disorder market size
is anticipated to contract significantly between 2014 and 2024,
driven largely by the generic erosion of Otsukas Abilify, the highest
selling bipolar disorder product in 2014. The uptake of novel
atypical antipsychotic products will be a principal driver of growth
over the forecast period, as these products offer clinical advantages
that will drive strong uptake. However, sales of these agents will be
limited by the continued utilization of established generic products.
There are currently only two products in Phase III development, which
indicates that bipolar disorder will remain a field of high unmet
need during the forecast period.
View Report At
:http://www.marketresearchreports.biz/analysis/725328
Highlights
Key Questions Answered
- The bipolar disorder market
is heavily genericized and many key players have chosen to
deprioritize the indication. In light of this, what are the current
clinical and environmental unmet needs? Will there be opportunities
in this market for drug developers throughout the forecast period?
- The current late-stage
bipolar disorder pipeline is sparse, with only two products in Phase
III development. What impact will these drugs have on the market? How
will they affect the treatment algorithm for bipolar disorder? Will
these drugs fulfil any of the unmet needs for bipolar disorder?
- The management of bipolar
disorder patients is challenging and a large number of variables can
impact treatment outcomes. How does the diagnosis and treatment of
bipolar disorder differ amongst the 8MM? Which treatment options are
most commonly prescribed in each market, and how will prescribing
patterns change over the forecast period?
Key Findings
- The main driver of growth in
the bipolar disorder market will be the uptake of novel atypical
antipsychotic products, such as Otsuka/Lundbecks Abilify Maintena and
Allergan/Gedeon Richter/Mitsubishi Tanabes Vraylar. These agents are
forecast to be the highest selling bipolar disorder products by 2024,
accounting for 34.9% of the bipolar disorder market in the 8MM.
- There are very few products
approved for the treatment of major depressive episodes, despite the
fact that patients most commonly experience this episode type. This
unmet need is not expected to be addressed during the forecast period
due to the sparsity of the late-stage pipeline.
- The biggest barrier for
growth in the bipolar disorder market will be fierce competition from
generic products. This limits market opportunities for new and
existing players, as uptake of novel pipeline products would be
hindered by their premium price point.
- Considerable opportunity
remains for products with superior safety profiles compared to the
currently available drugs. KOLs noted that EPS and metabolic changes
were significant concerns related to the antipsychotic drugs.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/725328
Scope
- Overview of bipolar disorder,
including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and treatment guidelines.
- Annualized bipolar disorder
market revenue, annual cost of therapy and treatment usage pattern
data from 2014 and forecast for ten years to 2024.
- Key topics covered include
market characterization, unmet needs, R&D and clinical trials
assessment, late stage clinical trial analysis and implications for
the bipolar disorder therapeutics market.
- Pipeline analysis: focus on
two late-stage pipeline bipolar disorder drugs, discussing emerging
trends as well as an overview of earlier phase drugs and a top-line
analysis of off-label treatments.
- Analysis of the current and
future market competition in the global bipolar disorder therapeutics
market. Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition
targets included in the pipeline product company list.
- Develop business strategies
by understanding the trends shaping and driving the global bipolar
disorder therapeutics market.
- Drive revenues by
understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global bipolar
disorder therapeutics market in future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players
with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the
global bipolar disorder therapeutics market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table
of Contents
1
Table of Contents 12
1.1
List of Tables 17
1.2
List of Figures 24
2
Introduction 26
2.1
Catalyst 26
2.2
Related Reports 27
2.3
Upcoming Related Reports 27
3
Disease Overview 28
3.1
Etiology and Pathophysiology 28
3.1.1
Etiology 28
3.1.2
Pathophysiology 30
3.2
Classification 34
3.3
Symptoms 40
3.4
Prognosis 41
4
Epidemiology 43
4.1
Disease Background 43
4.2
Risk Factors and Comorbidities 43
4.3
Global Trends 45
4.4
Forecast Methodology 47
4.4.1
Sources Used 53
4.4.2
Sources Not Used 56
4.4.3
Forecast Assumptions and Methods 56
4.5
Epidemiological Forecast of Bipolar Disorder (2014-2024) 60
4.5.1
12-Month Total Prevalent Cases of Bipolar Spectrum Disorder 60
4.5.2
12-Month Total Prevalent Cases of Bipolar I 61
4.5.3
12-Month Total Prevalent Cases of Bipolar II 63
4.5.4
12-Month Total Prevalent Cases of Cyclothymic Disorder 65
4.5.5
Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder 67
4.5.6
Age-Specific 12-Month Total Prevalent Cases of Bipolar I 68
4.5.7
Age-Specific 12-Month Total Prevalent Cases of Bipolar II 70
4.5.8
Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
72
4.5.9
Sex-Specific 12-Month Total Prevalent Cases of Bipolar I 74
4.5.10
Sex-Specific 12-Month Total Prevalent Cases of Bipolar II 76
4.5.11
Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder
78
4.5.12
Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum
Disorder 80
4.6
Discussion 82
4.6.1
Epidemiological Forecast Insight 82
4.6.2
Limitations of the Analysis 83
4.6.3
Strengths of the Analysis 84
5
Disease Management 85
5.1
Diagnosis Overview 85
5.1.1
Clinical Evaluation 85
5.1.2
Screening Tools 86
5.2
Treatment Overview 88
5.2.1
Treatment Initiation and Maintenance Therapy 88
5.2.2
Manic or Mixed Episodes 91
5.2.3
Acute Agitation 93
Read our latest Press
Release at http://www.marketresearchreports.biz/pressreleases
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment